Dr Reddys Laboratories Ltd
DRREDDY price chart
Daily close · 5-year history
Instrument details
Identifiers & classification
- Symbol
- DRREDDY
- MB Code
- MBEQU5085
- ISIN
- INE089A01031
- BSE code
- 500124
- Industry group
- Pharmaceuticals & Biotechnology
- Screener
- View peers →
Latest earnings
Most recent declared quarter
- Quarter
- Mar 2026
- Revenue
- 7546.4 Cr
- Net profit
- 221.3 Cr
- EPS
- 2.65
- YoY revenue
- -11.51%
Company documents
12 PDFs across 4 categories
Audited annual reports & financial statements
Earnings call transcripts & Q&A
Investor decks & strategy updates
Exchange filings & corporate announcements
Corporate timeline
Earnings, news & corporate actions for DRREDDY
Dr. Reddy's launched Bosutinib Tablets 400 mg in the US, the first generic Bosulif version, with 180-day first-to-file exclusivity and ex…
Dr. Reddy’s reported a 86% drop in Q4 profit to ₹221 crore on lower sales and multiple one-offs, underscoring margin pressure in the late…
Dr Reddy's shares are in focus after Q4 results showed profit plunging 86% year-on-year; the company also recommended a final dividend of…
Dr Reddy's shares swung on 13 May after Q4FY26 profit fell 86% YoY to ₹220 crore, with revenue down 11.6% and EBITDA down 60%; broker vie…
Dr Reddy’s Q4 FY26 net profit fell 86.2% to ₹220 crore as Revlimid competition, margin erosion and one-offs hit earnings; revenue dropped…
EPS 2.65 vs est. 11.40
Missed estimates by 76.76%
Dr Reddy's Q4 FY26 profit fell 86% YoY to Rs 221 crore on lower lenalidomide sales and one-offs; revenue slipped 12% to Rs 7,516 crore. B…
Dr Reddy's Q4 FY26 profit fell 86% to Rs 221.3 crore as North America generics sales dropped 51%; FY26 revenue rose to Rs 33,700.2 crore …
Price returns
Historical performance
Technicals
Indicator consensus